What Puragel Treats: Main Uses and Benefits

Puragel (Gelatin) plays a role in managing two distinct clinical needs by providing therapeutic support in clinical settings that involve either acute physiological needs or surgical intervention.

Primary Therapeutic Roles

This medication is commonly used to help address the severe, systemic manifestations of hypovolemic shock and extensive fluid loss resulting from severe trauma, hemorrhage, or burns. Its core therapeutic domain includes addressing the need for volume support in situations of significant blood loss, trauma, burns, and other conditions involving acute hypovolemia. Its primary benefit is the temporary restoration of plasma volume which may assist with the stabilization of low blood pressure (hypotension). This supportive action is commonly used in emergency and acute care settings for managing situations where there is significant volume deficit in the bloodstream. This assists with maintaining functional stability by supporting adequate circulation and organ perfusion.

---

The topical agent is relevant for managing localized bleeding and oozing from small vessels and raw tissue surfaces. This is often used during procedures across various surgical specialties, including neurosurgery, orthopedics, and ENT. The key benefit is its role in providing physical hemostasis, which is relevant for easing localized bleeding. This can contribute to supportive relief by managing the localized bleeding and supports wound management in the confined surgical field. The structural nature of the local agent also may assist with reducing the potential for certain post-surgical complications, such as adhesion risk.

---

Quick Fact: Relief for Acute Fluid Loss
Supports the patient during difficult episodes by easing distress related to low blood pressure and volume deficit.

Who Can and Cannot Use Puragel?

Eligibility for Puragel (Gelatin) is strictly defined by regulatory documents and depends on the specific formulation: the Intravenous (IV) Plasma Volume Expander or the Local Hemostatic Agent (surgical sponge).

---

Populations Who Must Not Use Puragel (Contraindications)

Contraindication	Applicable Form	Regulatory Basis
Known Hypersensitivity to gelatin or alpha-Gal (red meat allergy)	Both Forms	Absolute
Hypervolaemia or Acute Congestive Cardiac Failure	IV Expander	Circulatory Risk
End of Pregnancy	IV Expander	Fetal/Neonatal Risk
Intravascular Use or near the Optic Nerve/Dura Mater	Local Agent	Anatomical Risk

---

Population-Specific Restrictions

Age Restrictions: The use of both the IV Plasma Volume Expander and the Local Hemostatic Agent is not established regarding safety and effectiveness in the paediatric population (children). Use in older adults requires caution due to a higher likelihood of existing conditions like cardiac or renal insufficiency.

Organ Function and Conditions: The IV Expander should be used with caution in patients who have severe renal dysfunction, cardiac insufficiency, pulmonary impairment, or hepatic impairment. The Local Agent must not be used in the presence of infection.

Interactions with other medicines and products

Official regulatory documentation for Gelatin-based products (Puragel) defines its interaction profile based on physical and hemodynamic effects rather than traditional metabolic mechanisms.

Pharmacodynamic and Hemodynamic Interactions

For the intravenous formulation, a pharmacodynamic interaction risk exists with anticoagulant or antiplatelet medications. This is due to the potential for hemodilution of coagulation factors following the administration of large volumes of the plasma expander, which may increase the risk of bleeding. This effect is contingent upon the volume of the product administered.

Administration Restrictions (Topical Use)

The absorbable topical formulation carries specific regulatory restrictions concerning concurrent use with other materials encountered in the surgical field:

• Topical Hemostatic Agents: The safety and efficacy of concurrent use with agents like Topical Thrombin have not been evaluated in controlled clinical studies and are therefore not officially supported.
• Surgical Adhesives: The topical form must not be used in conjunction with methyl-methacrylate adhesives. This is a procedural prohibition based on the physical incompatibility of the materials, as the Gelatin product may compromise the adhesive strength used to attach prosthetic devices to bone.

Regulatory labels do not report clinically significant pharmacokinetic interactions involving cytochrome P450 enzymes or drug transporters.

How Puragel Works

The mechanism of action for Puragel is defined by its physical and structural properties, not by molecular interaction with specific receptors or enzymes.

The Trigger: Molecular Self-Assembly into a Hydrogel

Puragel consists of synthetic peptides that are in solution until they encounter the body's physiological fluids. The local pH and ionic concentration of the fluids act as the trigger, initiating a spontaneous molecular self-assembly of the peptides. This cascade causes the peptides to interlink into stable nanofibers, which form a robust, three-dimensional hydrogel mesh. This physical structure creates a structural barrier at the application site.

The Function: Bio-Mimetic Scaffolding and Degradation

The hydrogel structure is a bio-mimetic scaffold, physically resembling the natural Extracellular Matrix ( ECM). The scaffold physically separates adjacent tissue planes, limiting contact, and provides a temporary template that directs the migration of native cells involved in the reorganization of the tissue microenvironment. The synthetic material is designed to be resorbable; native enzymes like proteases catalyze the gradual hydrolysis and breakdown of the scaffold, ensuring the temporary structure is removed upon the conclusion of the tissue remodeling process.

How to Use Puragel (Absorbable Gelatin): Administration Overview

Puragel, a form of absorbable gelatin, is typically administered as a topical agent exclusively within a surgical setting to control localized bleeding. Its use is guided by specific procedural requirements.

Administration Scope

Category	Usage Instruction
Route of administration	Topical (Applied directly to the bleeding surface).
Dosing schedule	Qualitative Dose: Use only the minimum amount necessary to achieve hemostasis. No quantitative numeric dose is specified.
Preparation requirements	Sponge Form: May be used dry or saturated with sterile saline. Powder Form: Mixed with approximately 3–4 mL of sterile saline to create a paste.
Age-group administration rules	Pediatric Use: Safety and effectiveness have not been established in pediatric patients.

Resulting Procedural Structure

The use of Puragel is structured as a single, intra-operative application with two primary steps concerning final disposition. The applied material is designed to be left in place at the bleeding site, as it is fully absorbed by the body over a typical period of four to six weeks. This product is supplied sterile and cannot be resterilized after the package is opened. Special care is involved during application to avoid overpacking confined surgical areas, as the material expands significantly upon absorbing fluids. The goal is to apply only what is needed to manage the immediate local bleeding and ensure proper tissue integration during the absorption phase.

Research Evidence / Overview of Studies for Puragel (Gelatin)

---

1. Studies on Puragel as an Intravenous Plasma Volume Expander

Clinical research for the injectable form of Puragel has been studied for its study for fluid volume replacement and outcomes monitoring physiological strain or stress in adult patients who were observed in conditions associated with acute or disruptive episodes, such as trauma, major surgery, or severe fluid loss. Research examined high-level endpoints like all-cause mortality, the need for blood transfusions, and physiological parameters like blood pressure. Studies monitored rapid, measurable changes in plasma volume and evaluated the stabilization of blood pressure following infusion.

The trials reported that the Puragel solution was associated with these rapid changes, and comparative studies described patterns of fluid requirements across groups using different colloid and crystalloid solutions. For long-term outcomes, such as major survival and acute kidney function, the findings were mixed or varied across studies, contributing to the broader evidence landscape but not establishing conclusive findings.

---

2. Research on Puragel as a Local Hemostatic Agent

Research has explored the topical, solid form of Puragel (sponge or powder) through Randomized Controlled Trials (RCTs). These trials compared the outcomes of its use against conventional methods, such as packing with gauze, in adult patients undergoing various surgeries where outcomes related to physical discomfort and localized bleeding control are relevant. The primary measures used in research exploring how symptoms change over time included the precise Time to Hemostasis (how quickly bleeding stopped) and the volume of blood loss during the procedure.

Studies reported the gelatin material was observed in trials acting as a structural component at the bleeding site. Trials reported that the time required to achieve hemostasis when using the gelatin matrix was measured and compared against the time required for standard surgical practices to achieve the same result.

---

3. Evidence Consistency, Uncertainties, and Research Gaps

Across both the injectable and topical forms of Puragel, evidence quality varies across studies, and certainty remains low in some key areas. Because the focus has been on immediate or acute changes, long-term effects are not fully established for either use. Data are still emerging, and there is limited information for long-term outcomes concerning the durability of any observed effects.

Clinical trials have primarily focused on a broad population of critically ill and surgical adult patients. As a result, the data for certain groups, such as pediatric patients or those with specific comorbid conditions, remain insufficient or specialized. The research highlights what is known — and what is still uncertain — about this type of fluid and topical agent.

Common questions about Puragel (FAQ)

Q: How quickly does Puragel usually start to work?

Clinical studies measured successful hemostasis (the stopping of bleeding) within 10 minutes of application to the bleeding site. This measurement indicates the product’s intended rapid physical action.

Q: Is Puragel generally considered safe for long-term use?

Official product information describes Puragel as a surgical adjunct for short-term use. The material is fully resorbable, and is designed to be absorbed completely by the body over a period of four to six weeks.

Q: Does Puragel contain alcohol or any common allergens like parabens?

The product is composed of purified porcine gelatin (a protein derived from pigs) and water for injection. While the official documents note the risk of allergy to the porcine gelatin itself, alcohol and parabens are not listed as ingredients in the product’s description.

Q: How long does a course of Puragel treatment typically last?

Puragel is used as a single application during a surgical procedure. The treatment course is defined by the product’s absorption time, which is generally four to six weeks, as the body breaks down the material naturally.

Q: Does Puragel interact with common pain relievers like ibuprofen?

Regulatory documents state there are no known significant drug-drug interactions for the topical form of the product. The main interaction warnings concern certain surgical materials and anticoagulation factors related to the intravenous form.

Q: What is known about using Puragel during pregnancy or while breastfeeding?

Official warnings state that the amount of gelatin absorbed systemically after a topical application is unknown. Regarding breastfeeding, no specific data is currently available regarding the excretion of the drug in breast milk.

Q: Can I apply Puragel to large areas of my body?

Official instructions advise that only the minimum amount of Puragel necessary should be used. Product information also notes that care is required to avoid overpacking confined surgical spaces due to the material’s expansion, and excess material should be removed.

Q: Can Puragel be used with other topical creams for different conditions?

The product’s safety and efficacy have not been fully evaluated when used concurrently with most other agents. It is specifically not recommended in official documentation to saturate the material with antibiotic solutions or antibiotic powders.

Q: What are the signs that Puragel is working for me?

The product’s main function is to achieve hemostasis, or the stopping of bleeding, at the site of application. It works by creating a physical matrix that helps stabilize the blood clot formed during the surgical procedure.

Q: Can Puragel be bought over the counter, or is it prescription only?

Official regulations restrict this product to sale by or on the order of a physician or dentist. It is intended for professional use only within a sterile surgical or clinical setting.

Q: Can Puragel be used while taking common vitamin supplements?

Official regulatory documents state there are no known significant drug-drug interactions for the topical form of the product.

Q: Does Puragel interact with hormonal birth control pills?

Official regulatory documents state there are no known significant drug-drug interactions for the topical form of the product.

Q: What are the main things that could make Puragel less effective?

Official warnings indicate that effectiveness may be compromised if the product is used in the presence of frank infection. It is also specifically contraindicated for use with certain surgical adhesives, such as methyl-methacrylate.

Q: What happens if Puragel gets into my eyes or mouth?

Official indications state the product may be applied to bleeding surfaces including the oral and nasal mucosa. However, certain forms of the product are generally contraindicated for use in areas near the optic nerve or for ophthalmic (eye) procedures.

Q: Do I need to patch test Puragel before full use?

Puragel is restricted to use by a physician or dentist in a sterile surgical setting. However, official safety documentation notes that the product is contraindicated for use in patients with a known allergy to porcine collagen.

Q: How long does the effect of Puragel last after the treatment is finished?

The product acts as a temporary scaffold to support the natural clotting process and tissue healing. The material itself is fully broken down and absorbed by the body over a period of four to six weeks.

Q: Are there different strengths or concentrations of Puragel available?

The product is manufactured in different physical forms, such as sponges of various sizes and as a powder that can be mixed into a paste. However, the active ingredient, sterile absorbable porcine gelatin, is consistent across these forms.

The official storage and disposal guidelines for Puragel (Gelatin hemostatic agent) are designed to maintain its sterility and structural integrity as documented in regulatory labeling.

Storage Conditions

Puragel must be stored at controlled room temperature, typically 15 C to 30 C (59 F to 86 F), and kept dry. It must remain in its original, unopened, and undamaged package to preserve sterility. The product cannot be resterilized and must be stored out of the sight and reach of children.

Disposal Requirements

Any portion of the product that is unused after the package is opened must be discarded. Disposal of the unused or expired product must follow local procedures for medical waste and adhere to official pharmaceutical waste handling instructions to prevent environmental contamination.